Opening book details…
Can I read Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go? on EtoBox?
Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go? by Rannakoe J. Lehloenya; Jonny G. Peter; Ana Copascu; Jason A. Trubiano; Elizabeth J. Phillips is a Medicine article available to read on EtoBox.
What is Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go? about?
Delayed immune-mediated adverse drug reactions (IM-ADRs) are defined as reactions occurring more than 6 hours after dosing. They include heterogeneous clinical phenotypes that are typically T-cell-mediated reactions with distinct mechanisms across a wide spectrum of severity from benign exanthems through to life-threatening cutaneous or organ-specific diseases. For mild reactions such as benign exanthem, considerations for delabeling are similar to immediate reactions and may include a graded or single-dose drug challenge with or without preceding skin or patch testing. Evaluation of challenging cases such as the patient who is on multiple drugs at the time a severe delayed IM-ADR occurs should prioritize clinical ascertainment of the most likely phenotype and implicated drug(s). Although not widely available and validated, procedures such as patch testing, delayed intradermal skin testing, and laboratory-based functional drug assays or genetic (human leukocyte antigen) testing may provide valuable information to further help risk stratify patients and identify the likely implicated and/or cross-reactive drug(s). The decision to use a drug challenge as a diagnostic or delabeling to
Who reads Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go??
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Rannakoe J. Lehloenya; Jonny G. Peter; Ana Copascu; Jason A. Trubiano; Elizabeth J. Phillips
- Publisher
- Elsevier BV
- Published
- 2020
- Language
- EN
- Field
- Medicine (Health Sciences)